The path to leptomeningeal metastasis

Jean-Charles Soria shared a post on LinkedIn:  .

“Leptomeningeal metastasis occurs in 5-10% of patients with solid tumors and have a bleak prognosis. The pathways essential for leptomeningeal colonization remain unknown. Applying modern molecular systems biology and computational oncology approaches to leptomeningeal disease holds the potential to unravel the molecular and neuroanatomic basis for this complex disease process, enabling rational therapeutic targeting and potentially improved clinical outcomes.”

Visit the article website.
Source: Jean-Charles Soria/LinkedIn

Jean-Charles Soria serves as Amgen’s senior vice president of Oncology within Global Development. He is a medical oncologist and a professor of medicine at Paris-Saclay University. From 2017 to 2019, he was the senior vice president of Research and Development in Oncology at AstraZeneca. Additionally, Soria has authored or co-authored over 670 articles in leading international journals and has been recognized as one of the world’s most influential research scientists.